Vericel (NASDAQ:VCEL – Get Rating) will release its earnings data before the market opens on Wednesday, August 3rd. Analysts expect Vericel to post earnings of ($0.13) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Vericel (NASDAQ:VCEL – Get Rating) last released its earnings results on Wednesday, May 4th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). The company had revenue of $36.07 million during the quarter, compared to analyst estimates of $34.31 million. Vericel had a negative return on equity of 6.93% and a negative net margin of 7.15%. Vericel’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.07) earnings per share. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Vericel Price Performance
NASDAQ:VCEL opened at $28.55 on Wednesday. Vericel has a 1 year low of $22.42 and a 1 year high of $60.24. The company has a market cap of $1.35 billion, a P/E ratio of -114.20 and a beta of 1.93. The stock’s fifty day moving average price is $26.42 and its two-hundred day moving average price is $31.91.
Insiders Place Their Bets
Ad Investing Trends
US Govt. Injects $100’s of Millions Into Lithium
The government’s cash infusion could send lithium exploration companies soaring. They’re desperate for new lithium mines to end China’s Lithium Monopoly. See how you could take advantage of this enormous cash infusion.
In related news, Director Steven C. Gilman sold 900 shares of the firm’s stock in a transaction that occurred on Friday, April 29th. The shares were sold at an average price of $30.94, for a total value of $27,846.00. Following the sale, the director now directly owns 5,200 shares of the company’s stock, valued at $160,888. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.20% of the stock is owned by insiders.
Institutional Investors Weigh In On Vericel
Hedge funds and other institutional investors have recently modified their holdings of the stock. Engineers Gate Manager LP purchased a new position in Vericel during the 1st quarter valued at about $222,000. US Bancorp DE grew its holdings in shares of Vericel by 600.3% during the first quarter. US Bancorp DE now owns 6,184 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 5,301 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Vericel during the first quarter worth $240,000. Jane Street Group LLC boosted its holdings in Vericel by 223.3% in the first quarter. Jane Street Group LLC now owns 7,344 shares of the biotechnology company’s stock valued at $280,000 after acquiring an additional 13,299 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Vericel by 102.5% in the first quarter. Sei Investments Co. now owns 12,047 shares of the biotechnology company’s stock valued at $460,000 after acquiring an additional 6,097 shares during the last quarter.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. StockNews.com assumed coverage on Vericel in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Truist Financial dropped their target price on shares of Vericel to $33.00 in a report on Friday, July 22nd. TheStreet cut shares of Vericel from a “c-” rating to a “d+” rating in a research note on Thursday, March 31st. Finally, BTIG Research decreased their target price on shares of Vericel from $45.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, July 18th. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Vericel right now?
Before you consider Vericel, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Vericel wasn’t on the list.
While Vericel currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
